Table 1.
Baseline demographic and immunological characteristics of the participants who received two-dose vaccination.
| 1/10 dose | 1/5 dose | |||||
|---|---|---|---|---|---|---|
| 12-14 y.o. (n=13) |
15-17 y.o. (n=33) | Total (n=46) |
12-14 y.o. (n=13) |
15-17 y.o. (n=32) | Total (n=45) |
|
| Sex | ||||||
| Male | 7 (53.8) | 18 (54.5) | 25 (54.3) | 5 (38.5) | 22 (68.7) | 27 (60) |
| Female | 6 (46.2) | 15 (45.5) | 21 (45.7) | 8 (61.5) | 10 (31.3) | 18 (40) |
| Age,years | 13.5 (0.7) | 16.2 (0.8) | 15.5 (1.5) | 12.9 (0.9) | 16.0 (0.9) | 15.1 (1.6) |
| Ethnicity* | ||||||
| White | 13 (100) | 33 (100) | 46 (100) | 13 (100) | 32 (100) | 45 (100) |
| Height,cm | 164.3 (7.6) | 174.1 (9.4) | 171.3 (9.9) | 159.2 (8.5) | 176.6 (9.3) | 171.5 (12.0) |
| Weight,kg | 54.3 (13.5) | 66.0 (13.4) | 62.7 (14.3) | 54.1 (10.0) | 68.9 (15.8) | 64.6 (15.8) |
| Body mass index, kg/m2# | 19.9 (3.4) | 21.7 (3.3) | 21.2 (3.4) | 21.2 (2.9) | 22.0 (4.0) | 21.8 (3.7) |
| Immunity to SARS-CoV-2 | ||||||
|
Pre-existing anti-N
SARS-CoV-2 IgG antibodies$, N (%) |
0 (0) | 3 (9.1) | 3 (6.5) | 1 (7.7) | 6 (18.8) | 7 (15.6) |
| Pre-existing anti-S SARS-CoV-2 IgG antibodies$, N (%) | 1 (7.7) | 5 (15.2) | 6 (13.0) | 4 (30.7) | 10 (32.3) | 14 (31.1) |
| SARS-CoV-2 infection, presence of anti-N SARS-CoV-2 IgG antibodies$, N (%) | 3 (23.1) | 9 (27.3) | 12 (26.1) | 5 (38.5) | 7 (21.9) | 12 (26.7) |
Withdrawn participants (n=9) are excluded. The data are n (%) or mean (SD), unless otherwise stated. *Ethnic group was reported by the participants. #Calculation was based on the bodyweight and height measured at the time of screening. $Detection of seropositive participants was done referring to the threshold for positivity set by the manufacturer (Vector-Best ELISA kits) Bold values represent summarized results for each dose